Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration | Zendy

Matti Karvanen | Zendy; Diamantis Plachouras | Zendy; Lena E. Friberg | Zendy; Elisabeth Paramythiotou | Zendy; Evangelos Papadomichelakis | Zendy; Ilias Karaiskos | Zendy; Iraklis Tsangaris | Zendy; Apostolos Armaganidis | Zendy; Otto Cars | Zendy; Helen Giamarellou | Zendy

Open Access

Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration

Author(s) -

Matti Karvanen,

Diamantis Plachouras,

Lena E. Friberg,

Elisabeth Paramythiotou,

Evangelos Papadomichelakis,

Ilias Karaiskos,

Iraklis Tsangaris,

Apostolos Armaganidis,

Otto Cars,

Helen Giamarellou

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00985-12

Subject(s) - colistin , pharmacokinetics , critically ill , medicine , intensive care medicine , critical illness , pharmacology , anesthesia , antibiotics , chemistry , biochemistry

This report describes the pharmacokinetics of colistin methanesulfonate (CMS) and colistin in five intensive care unit patients receiving continuous venovenous hemodiafiltration. For CMS, the mean maximum concentration of drug in plasma (C max ) after the fourth dose was 6.92 mg/liter and total clearance (CL) 8.23 liters/h. For colistin, the mean concentration was 0.92 mg/liter and CL/metabolized fraction (fm ) 18.91 liters/h. Colistin concentrations were below the current MIC breakpoints, and the area under the concentration-time curve for the free, unbound fraction of the drug over 24 h in the steady state divided by the MIC (f AUC/MIC) was lower than recommended, suggesting that a dosage regimen of 160 mg CMS every 8 h (q8h) is inadequate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research